Incidence of cytomegalovirus disease in renal transplantation without antilymphocyte induction: is prophylaxis necessary?
Smith
S R
SR
Department of Medicine, Duke University Medical Center, Durham, North Carolina, 27710 USA.
Butterly
D W
DW
Conlon
P J
PJ
Harland
R C
RC
Emovon
O E
OE
D000212:Acyclovir / Q000627:therapeutic use*; D000328:Adult; D000704:Analysis of Variance; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D003586:Cytomegalovirus Infections / Q000453:epidemiology* / Q000517:prevention & control*; D006085:Graft Survival; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015994:Incidence; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology*; D011183:Postoperative Complications / Q000453:epidemiology*; D011241:Prednisone / Q000627:therapeutic use; D015995:Prevalence; D012189:Retrospective Studies
D000961:Antilymphocyte Serum; D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D001379:Azathioprine; D011241:Prednisone; D000212:Acyclovir